References
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97. https://doi.org/10.1016/S1474-4422(11)70246-0 PMid:22094129
- Adams D, Beaudonnet G, Adam C, Lacroix C, Théaudin M, Cauquil C, et al. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?. Rev Neurol. 2016;172(10):645-52. https://doi.org/10.1016/j.neurol.2016.08.007 PMid:27663057
- Nuvolone M, Obici L, Merlini G. Transthyretin-associated familial amyloid polyneuropathy-current and emerging therapies. US Neurol. 2012;8:24-32. https://doi.org/10.5167/uzh-69213
- Escolano-Lozano F, Barreiros AP, Birklein F, Geber C. Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis. Brain Behav. 2018;8(1):e00889. https://doi.org/10.1002/brb3.889 PMid:29568686
- Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057-62. https://doi.org/10.1001/archneur.62.7.1057 PMid:16009758
- Shrestha S, Munakomi S. Gower sign. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540973 [Last accessed on 2023 Feb 13].
- Dugo K, Bruno F, Sturiale V, Brancato D, Saccone S, Federico C. Hereditary transthyretin-related amyloidosis: Genetic heterogeneity and early personalized gene therapy. Biomedicines. 2022;10(10):2394. https://doi.org/10.3390/biomedicines10102394 PMid:36289657
- Takei YI, Ikeda SI, Ikegami T, Hashikura Y, Miyagawa SI, Ando Y. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: Outcomes of living donor liver transplantations. Intern Med. 2005;44(11):1151-6. https://doi.org/10.2169/internalmedicine.44.1151 PMid:16357452
- Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3-13. https://doi.org/10.1097/WCO.0000000000000288 PMid:26734951
- Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J. 2022;18(2):17-26. https://doi.org/10.14797/mdcvj.1066 PMid:35414855
- Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9. https://doi.org/10.1111/jns.12153 PMid:26663427
- Planté-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: A clinical and neurophysiological study. J Neurol. 2017;264:268-76. https://doi./org/10.1007/s00415-016-8337-3 PMid:27878441
- Scott LJ. Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs. 2014;74(12):1371-8. https://doi.org/10.1007/s40265-014-0260-2 PMid:25022953
- Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14-26. https://doi.org/10.1097/WCO.0000000000000289 PMid:26734952
- Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: Clinical trial results up to 8.5 years. Neurol Ther. 2020;9(1):105-15. https://doi.org/10.1007/s40120-020-00180-w PMid:32107748
- Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. https://doi.org/10.1056/NEJMoa1716153 PMid:29972753
- Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142. https://doi.org/10.1038/s41467-021-23274-x PMid:34035264
- Tschöpe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med. 2022;11(8):2148. https://doi.org/10.3390/jcm11082148 PMid:35456241